English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 45422/58598 (78%)
造訪人次 : 2555318      線上人數 : 153
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋


    請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/6506


    題名: 去乙醯幾丁聚醣之非對稱性膜滲透膠囊之製備與特性解析
    Characterization of Osmotic Capsule with Asymmetric Membrane Using Chitosan
    作者: 王聖希
    Sheng Shi Wang
    貢獻者: 藥學研究所
    關鍵詞: 去乙醯幾丁聚醣
    非對稱性膜
    滲透膠囊
    chitosan
    asymmertric membrane
    osmotic capsule
    日期: 2004
    上傳時間: 2009-09-11 16:57:47 (UTC+8)
    摘要: 去乙醯幾丁聚醣之非對稱性膜滲透膠囊之製備與特性解析
    中 文 摘 要
    本研究主要目的是要以去乙醯幾丁聚醣(Chitosan)來當作非對稱性膠囊之材質，設計合適的滲透性控釋膠囊。非對稱性膜在膠囊化處理後可改善滲透性幫浦難溶性藥物釋放的情形。 膠囊殼乃是以交聯的方式膠化所產生，先將模具浸入含有聚合物的包覆溶液(coating solution)，再浸入到淬鍊溶液(quenching solution)，而在膜具上形成具有非對稱結構之膠囊殼。選用不同的膜衣材質，包覆溶液，浸漬溶液和浸漬時間來製作並評估非對稱結構之膠囊殼之特性。
    滲透壓實驗中，薄膜釋藥孔之存在由包覆葉綠素的膠囊緩緩釋出葉綠素而得到證實。選用不同溶解度的藥物來評估對稱性膠囊的控釋效果。結果顯示藥物從非對稱性膜膠囊的釋放會因藥物的溶解度增加而增加，藥物的溶出速率與藥物溶解度成線性相關。在實用的觀點下考量製作難易度及通透效果後，選取以去乙醯幾丁聚醣與三磷酸鹽交聯三十分鐘這組膠囊為試驗膠囊。膠囊的通透率經計算而得 1.40*10-6 cm2/h-atm 於 攝氏37.8度，因為難溶性藥物felodipine 及 nifedipine不能提供足夠的滲透壓動力，於是在處方中添加助溶劑SLS 或添加助懸劑 HPMC 以增加藥物釋放。經計算而得之複回歸方程式:
    YF(drug max released %)= 32.48367-1.04456* F+0.14909 * H+ 0.23256 * S(mg)
    YN(drug max released %)= 30.99458-0.95958 * N+0.12802 * H+0.21321 * S(mg)
    最後，我們成功地設計出以去乙醯幾丁聚醣與三磷酸鹽 (TPP)交聯之非對稱性滲透膠囊。
    Characterization of Osmotic Capsule with Asymmetric Membrane Using Chitosan
    ABSTRACT
    The major purpose of the study was to devise a suitable osmotic capsule for drug release. In this study, chitosan was utilized as the matrix of asymmetric membrane capsules. Asymmetric membrane offering an improved osmotic pump effect was used to release poorly water-soluble drug in a control manner after encapsulation. The capsule wall was composed of membrane produced by gelation process, controlled by the ionic cross-linking reaction between protonated chitosan and ionized triphosphate (TPP). Asymmetric membrane was formed on stainless steel mold pins by dipping the mold pins into a coating solution containing a polymeric material followed by dipping into a quenching solution. The factors influenced the prosperities of the capsule membrane, such as the molecular weight of chitosan、the solvent、the dipping solution and the dipping time were investigated in view of the drug release.
    In situ formation of a delivery orifice in the thin membrane was proven by observation of a jet stream of chlorophyll being released from the capsule. Drugs with different solubility were selected as the model to demonstrate that the controlled release characteristics can be manipulated by the design of polymeric capsule coating an asymmetric membrane. The results showed that the release rate from asymmetric membrane capsule increased with the solubility for drugs. A correlation between drug solubility and the initial drug release rate calculated from the slope of the drug release profile was verified to be linear. From the practical viewpoint it is useful to estimate selectivity of the capsules towards the difficulty of production and permeability. The model capsule made of chitosan 500 cross-linked with triphosphate. Permeability across the selected asymmetric membrane of the C500/TPP30 capsule was determined to be 1.40*10-6 cm2/h-atm at 37.8OC for drugs with water solubilities in a moderate to high range. The poorly water-soluble drug, felodipine and nifedipine, were unable to create a sufficient osmotic effect on activating the release of drug. Solubilization either by the addition of the solubility enhancer, SLS, or by a solid dispersion with HPMC could increase the solubility of nifedipine to a sufficient extent to activate drug release. It was found that HPMC further interacted with SLS to synergistically increase the maximal percent of release amount and the release rate of felodipine and nifedipine.
    The multi regression formulations of felodipine and nifedipine were “YF( drug max released %) =32.48367-1.04456*F+0.14909*H+0.23256*S(mg)” and“YN(drug max released%) =30.99458-0.95958*N+0.12802*H+0.21321*S(mg)”, respectively. Consequently, we successfully designed the osmotic capsule with asymmetric membrane which was made of chitosan and cross-linked with TPP.
    資料類型: thesis
    顯示於類別:[藥學系] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    摘要.doc29KbMicrosoft Word101檢視/開啟
    摘要.pdf66KbAdobe PDF170檢視/開啟
    摘要.ppt109KbMicrosoft Powerpoint145檢視/開啟
    摘要.ps389KbPostscript77檢視/開啟


    在TMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    著作權聲明 Copyright Notice

    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋